author-photo

Ameeta A. Patel

University of Texas MD Anderson Cancer Center

23

Papers

658

Citations

Citation Trend

Filter By

Papers (18) Sort By

Journal Conference Others

Combined inhibition of Rad51 and Wee1 enhances cell killing in HNSCC through induction of apoptosis associated with excessive DNA damage and replication stress.

2021 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (3)
Effects of Low-dose Triple Combination Therapy on Time at Target Blood Pressure – Results From the TRIUMPH Randomized Controlled Trial

2021 Heart Lung and Circulation
Show All
- Source
- Cite
- Save
Citations (0)
021 Effects of Low-dose Triple Combination Therapy on Therapeutic Inertia and Prescribing Patterns in Hypertension – Results from the TRIUMPH Trial

2020 Heart Lung and Circulation
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PR08: Inhibition of ATR as a therapeutic strategy to overcome cisplatin resistance in HNSCC

2020 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
COTI-2, a novel thiosemicarbazone derivative, exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms

2019 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (30)
Disruption of TP63-miR-27a* feedback loop by mutant TP53 in head and neck cancer

2019 Journal of the National Cancer Institute
Show All
- Source
- Cite
- Save
Citations (3)
Targeting the DNA Damage Response in OSCC with TP53 Mutations

2018 Journal of Dental Research
Show All
- Source
- Cite
- Save
Citations (32)
Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity

2018 Oral Oncology
Show All
- Source
- Cite
- Save
Citations (47)
Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1

2018 Oncogene
Show All
- Source
- Cite
- Save
Citations (29)
Replication stress leading to apoptosis within the S-phase contributes to synergism between vorinostat and AZD1775 in HNSCC harboring high risk TP53 mutation

2017 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (18)